Comment for Type of Reporting Person:  (1) The shares of common stock (the "Shares") of Glucotrack, Inc. (the "Issuer") reported herein represent (i) 77,492 Shares held by White Lion Capital LLC ("White Lion"), and (ii) additional Shares that may be acquired by White Lion pursuant to (a) a common stock purchase agreement (the "Stock Purchase Agreement") with an effective date of July 14, 2026, between the Issuer and White Lion, as amended pursuant to the Amendment No. 1 to the Stock Purchase Agreement (the "Amendment"), (b) commitment shares held in abeyance ("Abeyance Shares"), (c) commitment share common warrants ("Common Warrants"), (d) a securities purchase agreement (the "Securities Purchase Agreement"), (e) a senior convertible promissory note (the "Note"), and (f) common share warrants issued pursuant to the Securities Purchase Agreement (the "SPA Warrants"). Under the Common Warrants, the Note, and the SPA Warrants, White Lion may acquire Shares (or securities convertible into or exercisable for Shares) in accordance with the respective terms and subject to the respective conditions and limitations contained therein. One of such limitations is that White Lion is prohibited from acquiring any Shares under the Common Warrants, which, when aggregated with all other Shares then beneficially owned by White Lion and its affiliates, would result in the beneficial ownership by the Fund and its affiliates to exceed 4.99% of the Shares outstanding (the "Common Warrant Ownership Limitation"). White Lion may increase the Common Warrant Ownership Limitation up to 9.99% upon sixty-one (61) days prior written notice to the Issuer. Another limitation is that White Lion is prohibited from acquiring any Shares under the Note which, when aggregated with all other Shares then beneficially owned by White Lion and its affiliates, would result in the beneficial ownership by the Fund and its affiliates to exceed 4.9% of the Shares outstanding (the "Note Ownership Limitation"). White Lion may increase the Note Ownership Limitation up to 9.9% upon written notice to the Issuer. Another limitation is that White Lion is prohibited from acquiring any Shares under the SPA Warrants, which, when aggregated with all other Shares then beneficially owned by White Lion and its affiliates, would result in the beneficial ownership by the Fund and its affiliates to exceed 4.99% of the Shares outstanding (the "SPA Warrant Ownership Limitation"). White Lion may increase the SPA Warrant Ownership Limitation up to 9.99% upon sixty-one (61) days prior written notice to the Issuer. Furthermore, under the Stock Purchase Agreement, at the Issuer's sole discretion, White Lion may be required to purchase Shares, in accordance with the terms and subject to the conditions and limitations of the Purchase Agreement. One of such limitations is that the Fund is prohibited from acquiring any Shares under the Purchase Agreement, which, when aggregated with all other Shares then beneficially owned by the Fund and its affiliates, would result in the beneficial ownership by the Fund and its affiliates to exceed 4.99% of the Shares outstanding (the "Purchase Agreement Ownership Limitation" and together with the Common Warrant Ownership Limitation, the Note Ownership Limitation, and the SPA Warrant Limitation, the "Ownership Limitations"). For the sake of clarity, White Lion owns 77,492 Shares as of the date of the filing and currently has no right to acquire Shares currently held in abeyance or upon exercise of outstanding Common Warrants, and Note as of the date of the filing due to the Ownership Limitations. Solely for the purposes of Rule 13d-3 and this Schedule 13G, White Lion is filing this report to reflect that it may beneficially own Shares pursuant to the Stock Purchase Agreement, Common Warrants, Note, and SPA Warrants as if the Ownership Limitations were 9.99% even if, in the future, it ceases to hold the Shares it currently holds. The filing of this report shall not be deemed an admission, for purposes of Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. (2) Calculated in accordance with Rule 13d-3 promulgated under the Exchange Act and based on 798,144 shares of Common Stock outstanding as of August 28, 2026.